Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats

Kidney Blood Press Res. 2012;35(5):382-92. doi: 10.1159/000336823. Epub 2012 Apr 4.

Abstract

Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ET(A)) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats. Therefore, we were interested in whether ET(A) receptor blockade could have additive effects to the classical blockade of the RAS. Transgenic rats underwent 5/6 renal ablation at the age of 2 months and were treated for 20 weeks with RAS blockers alone (angiotensin II receptor blocker - losartan, and angiotensin-converting enzyme inhibitor - trandolapril), ET(A) receptor blocker alone (atrasentan) or with the combination of RAS and ET(A) receptor blockade. RAS blockade normalized blood pressure and improved survival. It decreased cardiac hypertrophy and proteinuria as well as tissue angiotensin II and ET-1 levels. In contrast, ET(A) receptor blockade only partially improved survival rate, reduced blood pressure, attenuated the development of cardiac hypertrophy and transiently reduced proteinuria. However, no additive cardio- and renoprotective effects of ET(A) and RAS blockade were noted at the end of the study.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Atrasentan
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Endothelin A Receptor Antagonists*
  • Hypertension, Renal / drug therapy*
  • Hypertension, Renal / mortality
  • Hypertension, Renal / pathology
  • Indoles / pharmacology*
  • Kidney / pathology
  • Losartan / pharmacology*
  • Male
  • Nephrectomy / methods
  • Pyrrolidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Rats, Transgenic
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Endothelin A / metabolism
  • Renal Insufficiency, Chronic / drug therapy
  • Renal Insufficiency, Chronic / mortality
  • Renal Insufficiency, Chronic / pathology
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology
  • Survival Analysis
  • Treatment Outcome

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Endothelin A Receptor Antagonists
  • Indoles
  • Pyrrolidines
  • Receptor, Angiotensin, Type 1
  • Receptor, Endothelin A
  • trandolapril
  • Losartan
  • Atrasentan